Pharmacodynamics of Ceftazidime plus the Serine β-Lactamase Inhibitor AM-112 against Escherichia coliContaining TEM-1 and CTX-M-1 β-Lactamases

ABSTRACTA strain of Escherichia colicontaining TEM-1 and CTX-M-1 was tested in an in vitro pharmacokinetic model against ceftazidime with and without AM-112, a serine β-lactamase inhibitor. Ceftazidime alone was less effective than ceftazidime plus AM-112, and a single dose was more effective than three fractionated doses.